{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:40:08Z","timestamp":1783665608306,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Proteomics Clinical Apps"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Percutaneous transluminal coronary angioplasty (PTCA) is an effective procedure to decrease the severity of stenotic coronary atherosclerotic lesions. However, its long\u2010term success is limited by the formation of restenosis or neointima by increased proliferation of smooth muscle cells (SMCs) and synthesis of extracellular matrix. Polypeptide growth factors are potent SMC mitogens and are involved in SMC proliferation and extracellular matrix (ECM) synthesis. In this line, inhibition of de novo protein synthesis might be beneficial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined the effects of different concentrations of translational inhibitor puromycin on SMC proliferation and apoptosis, in vitro. Further, we examined the effects of local administration of puromycin in a rabbit balloon injury model of the iliac artery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Injection of puromycin or its vehicle was performed with an infusion\u2010balloon catheter directly into the vessel wall during angioplasty. PTA in the vehicle group resulted in neointima formation 3 weeks after the vascular intervention. In contrast, puromycin treatment resulted in a significant reduction of intima\u2013media ratio. We observed decreased elastin and collagen III synthesis in puromycin\u2010treated animals. With proteomics, we could demonstrate reduced protein expression of lamin, vimentin, alpha\u20101 antitrypsin, alpha\u2010actin allowing puromycin treatment. In in vitro experiments, puromycin decreased SMCs proliferation (i.e., BrdU incorporation) following FCS stimulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Perspective<\/jats:title><jats:p>Based on the data from our animal experiments, aministration of puromycin directly into the vessel wall during angioplasty may be effective in preventing or reducing restenosis in humans.<\/jats:p><\/jats:sec>","DOI":"10.1002\/prca.202400066","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:33:20Z","timestamp":1740558800000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intramural Administration of Translational Inhibitor Puromycin Upon Balloon Angioplasty Inhibits SMC Proliferation and Protein Synthesis\u2013Vascular Proteome Profiling Analysis"],"prefix":"10.1002","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0534-132X","authenticated-orcid":false,"given":"Priyanka","family":"Boettger","sequence":"first","affiliation":[{"name":"Department of Medicine II Cardiology Intensive Care Medicine, Angiology St. Marien Hospital  Siegen Germany"},{"name":"Department of Medicine III Martin\u2010Luther\u2010University Halle\u2010Wittenberg  Halle\/Saale Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00f6rg","family":"Schwertz","sequence":"additional","affiliation":[{"name":"Molecular Medicine Program The University of Utah  Salt Lake City Utah USA"},{"name":"Division of Occupational Medicine The University of Utah  Salt Lake City Utah USA"},{"name":"Department of Occupational Medicine Billings Clinic Bozeman  Bozeman Montana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Platsch","sequence":"additional","affiliation":[{"name":"BASF SE  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Mueller\u2010Werdan","sequence":"additional","affiliation":[{"name":"Department of Medicine III Martin\u2010Luther\u2010University Halle\u2010Wittenberg  Halle\/Saale Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Werdan","sequence":"additional","affiliation":[{"name":"Department of Medicine III Martin\u2010Luther\u2010University Halle\u2010Wittenberg  Halle\/Saale Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5477-9957","authenticated-orcid":false,"given":"Michael","family":"Buerke","sequence":"additional","affiliation":[{"name":"Department of Medicine II Cardiology Intensive Care Medicine, Angiology St. Marien Hospital  Siegen Germany"},{"name":"Department of Medicine III Martin\u2010Luther\u2010University Halle\u2010Wittenberg  Halle\/Saale Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642737"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead083"},{"issue":"2","key":"e_1_2_9_4_1","first-page":"149","article-title":"Update on Pharmacology for Restenosis","volume":"3","author":"Chan A. W.","year":"2001","journal-title":"Current Interventional Cardiology Reports"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa121"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12033\u2010021\u201000341\u20108"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026378"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/342142a0"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02618254"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2024.106848"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005\u20102736(93)90125\u2010j"},{"issue":"9","key":"e_1_2_9_12_1","first-page":"1441","article-title":"[Reliable Micromethod for Determination of the Protein Content in Tissue Homogenates]","volume":"34","author":"Popov N.","year":"1975","journal-title":"Acta Biologica Et Medica Germanica"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/elps.1150090106"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220961038"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.29.3.411"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022\u20102836(65)80229\u20107"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005\u20102787(68)90187\u20101"},{"issue":"5","key":"e_1_2_9_18_1","first-page":"1761","article-title":"Puromycin Is a Potent and Specific Inhibitor of Tyrosine Kinase Activity in HL\u201060 Cells","volume":"12","author":"Davidoff A. N.","year":"1992","journal-title":"Anticancer Research"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1081881"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.06.006"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054950"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.100.10.1109"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103630"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123688"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.49871"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100147"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011\u2010012\u20100568\u2010x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1009908"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1000760"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2012.02.004"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.317491"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab140"}],"container-title":["PROTEOMICS \u2013 Clinical Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prca.202400066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T01:39:52Z","timestamp":1747100392000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/prca.202400066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/prca.202400066"],"URL":"https:\/\/doi.org\/10.1002\/prca.202400066","archive":["Portico"],"relation":{},"ISSN":["1862-8346","1862-8354"],"issn-type":[{"value":"1862-8346","type":"print"},{"value":"1862-8354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"2024-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e202400066"}}